Stephanie Willerth's guest appearances

Stephanie Willerth

The Stem Cell Podcast

BEaTS Research Radio's Podcast

The Lattice (Official 3DHEALS Podcast)

Nicole Quinn

Chris Smith

David Piper

Michael Levin

Austin Smith

Robert Mays

Kiki Sanford

Bernie Siegel

Greg Smith

Aubrey de Grey

Kaytlyn Gerbin

Chuck Murry

Sarthak Sinha

Kevin Yoder

Andrew Cohen

OwlTail

In this episode, I had the pleasure to chat with professor Stephanie Willerth at the University of Victoria, also the founder of Axolotl Biosciences.Stephanie is not only an expert in bioprinting and bioinks in general, but also one of a few scientists in the world focusing on using 3D cell models on common but devastating neurological diseases such as GBM, Parkinson's Disease, and Alzheimer's Disease. We started with some basic concepts related to bioprinting, bioinks, organoids, and organ-on-a-chip, and some of the general current applications and ongoing researches. All of these technologies, however, require sophisticated bioink formulation to achieve structural and functional goals. Also, who are the major players in commercial bioprinting? Other versions of this episode: WebsiteInstagramAxolotl BiosciencesWillerth LabYoutubePast blog by prof. Willerth: 3D Bioprinting Glioblastoma Models for Drug Screening3D Bioprinting Personalized Brain TissuesAbout Our Guest:Dr. Willerth holds a Canada Research Chair in Biomedical Engineering at the University of Victoria where she has dual appointments in the Department of Mechanical Engineering and the Division of Medical Sciences as an Associate Professor.She serves as the Acting Director for the Centre for Biomedical Research at the University of Victoria and on the steering committee of the B.C. Regenerative Medicine Initiative. She also served as the President of the Canadian Biomaterials Society from 2017-2018. Her honors include being named the 2018 REACH award winner for Excellence in Undergraduate Research-inspired Teaching, a Woman of Innovation in 2017, one of the 2015 Young Innovators in Cellular and Biological Engineering, and a “Star in Global Health” by Grand Challenges Canada in 2014. She spent the Fall of 2016 on sabbatical at the Wisconsin Institute for Discovery supported by the International Collaboration on Repair Discoveries International Travel Award where she wrote her book “Engineering neural tissue using stem cells” published by Academic Press.She completed her postdoctoral work at the University of California-Berkeley after receiving her Ph.D. in Biomedical Engineering from Washington University. Her undergraduate degrees were in Biology and Chemical Engineering from the Massachusetts Institute of Technology.Support the show (https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url)

In this episode, I had the pleasure to chat with professor <a href="https://www.linkedin.com/in/stephanie-willerth-2473587b/" rel="nofollow" target="_blank">Stephanie Willerth</a> at the University of Victoria, also the founder of <a href="https://www.instagram.com/axolotlbiosciences/?hl=en" rel="nofollow" target="_blank">Axolotl Biosciences</a>.Stephanie is not only an expert in bioprinting and bioinks in general, but also one of a few scientists in the world focusing on using 3D cell models on common but devastating neurological diseases such as GBM, Parkinson's Disease, and Alzheimer's Disease. We started with some basic concepts related to bioprinting, bioinks, organoids, and organ-on-a-chip, and some of the general current applications and ongoing researches. All of these technologies, however, require sophisticated bioink formulation to achieve structural and functional goals. Also, who are the major players in commercial bioprinting?  Other versions of this episode: <a href="https://3dheals.com/interview-with-prof-stephanie-willerth-bioprinting-brain-and-axolotl-biosciences" rel="nofollow" target="_blank">Website</a><a href="https://www.instagram.com/tv/CNnPPRAjxL6/?utm_source=ig_web_copy_link" rel="nofollow" target="_blank">Instagram</a><a href="https://www.axolotlbiosciences.com/" rel="nofollow" target="_blank">Axolotl Biosciences</a><a href="https://www.engr.uvic.ca/~willerth/index.shtml" rel="nofollow" target="_blank">Willerth Lab</a><a href="https://youtu.be/GhsxtNIU1rA" rel="nofollow" target="_blank">Youtube</a>Past blog by prof. Willerth: <h1><a href="https://3dheals.com/3d-bioprinting-glioblastoma-models-for-drug-screening" rel="nofollow" target="_blank">3D Bioprinting Glioblastoma Models for Drug Screening</a></h1><a href="https://3dheals.com/3d-bioprinting-personalized-brain-tissues" rel="nofollow" target="_blank">3D Bioprinting Personalized Brain Tissues</a>About Our Guest:Dr. Willerth holds a Canada Research Chair in Biomedical Engineering at the University of Victoria where she has dual appointments in the Department of Mechanical Engineering and the Division of Medical Sciences as an Associate Professor. She serves as the Acting Director for the Centre for Biomedical Research at the University of Victoria and on the steering committee of the B.C. Regenerative Medicine Initiative. She also served as the President of the Canadian Biomaterials Society from 2017-2018. Her honors include being named the 2018 REACH award winner for Excellence in Undergraduate Research-inspired Teaching, a Woman of Innovation in 2017, one of the 2015 Young Innovators in Cellular and Biological Engineering, and a “Star in Global Health” by Grand Challenges Canada in 2014. She spent the Fall of 2016 on sabbatical at the Wisconsin Institute for Discovery supported by the International Collaboration on Repair Discoveries International Travel Award where she wrote her book “Engineering neural tissue using stem cells” published by Academic Press. She completed her postdoctoral work at the University of California-Berkeley after receiving her Ph.D. in Biomedical Engineering from Washington University. Her undergraduate degrees were in Biology and Chemical Engineering from the Massachusetts Institute of Technology.<a href="https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url" rel="payment nofollow" target="_blank">Support the show</a> (<a href="https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url" rel="nofollow" target="_blank">https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url</a>)

Interview with CEO of Axolotl Biosciences, Prof. Stephanie Willerth: Bioprinting Brain and More

A fascinating conversation with upcoming 3DHEALS2020 speaker Dr. Stephanie Willerth on where bioprinting and biofabrication technology is to help with drug development and screening of neurological diseases such as Alzheimer's disease if we can create tissue replacements, "mini-brain", as well as her new bio-ink startup, Axolotl Biosciences. See the full interview here. Dr. Willerth holds a Canada Research Chair in Biomedical Engineering at the University of Victoria where she has dual appointments in the Department of Mechanical Engineering and the Division of Medical Sciences as an Associate Professor.She serves as the Acting Director for the Centre for Biomedical Research at the University of Victoria and on the steering committee of the B.C. Regenerative Medicine Initiative. She also served as the President of the Canadian Biomaterials Society from 2017-2018. Her honors include being named the 2018 REACH award winner for Excellence in Undergraduate Research-inspired Teaching, a Woman of Innovation in 2017, one of the 2015 Young Innovators in Cellular and Biological Engineering and a “Star in Global Health” by Grand Challenges Canada in 2014.  She spent Fall of 2016 on sabbatical at the Wisconsin Institute for Discovery supported by the International Collaboration on Repair Discoveries International Travel Award where she wrote her book “Engineering neural tissue using stem cells” published by Academic Press.She completed her postdoctoral work at the University of California-Berkeley after receiving her Ph.D. in Biomedical Engineering from Washington University. Her undergraduate degrees were in Biology and Chemical Engineering from the Massachusetts Institute of Technology. Dr. Willerth will be speaking at the upcoming virtual 3DHEALS2020.Support the show (https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url)

A fascinating conversation with upcoming 3DHEALS2020 speaker Dr. Stephanie Willerth on where bioprinting and biofabrication technology is to help with drug development and screening of neurological diseases such as Alzheimer's disease if we can create tissue replacements, "mini-brain", as well as her new bio-ink startup, Axolotl Biosciences. See the full interview <a href="https://3dheals.com/interview-with-stephanie-willerth-bioprinting-brain" rel="nofollow" target="_blank">here</a>. Dr. Willerth holds a Canada Research Chair in Biomedical Engineering at the University of Victoria where she has dual appointments in the Department of Mechanical Engineering and the Division of Medical Sciences as an Associate Professor.She serves as the Acting Director for the Centre for Biomedical Research at the University of Victoria and on the steering committee of the B.C. Regenerative Medicine Initiative. She also served as the President of the Canadian Biomaterials Society from 2017-2018. Her honors include being named the 2018 REACH award winner for Excellence in Undergraduate Research-inspired Teaching, a Woman of Innovation in 2017, one of the 2015 Young Innovators in Cellular and Biological Engineering and a “Star in Global Health” by Grand Challenges Canada in 2014.  She spent Fall of 2016 on sabbatical at the Wisconsin Institute for Discovery supported by the International Collaboration on Repair Discoveries International Travel Award where she wrote her book “Engineering neural tissue using stem cells” published by Academic Press.She completed her postdoctoral work at the University of California-Berkeley after receiving her Ph.D. in Biomedical Engineering from Washington University. Her undergraduate degrees were in Biology and Chemical Engineering from the Massachusetts Institute of Technology. Dr. Willerth will be speaking at the upcoming virtual <a href="https://www.3dheals2020.com/" rel="nofollow" target="_blank">3DHEALS2020</a>.<a href="https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url" rel="payment nofollow" target="_blank">Support the show</a> (<a href="https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url" rel="nofollow" target="_blank">https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&amp;hosted_button_id=STF9STPYVE2GG&amp;source=url</a>)

Interview with Stephanie Willerth, Bioprinting Brain and Axolotl Biosciences

Guest:Dr. Stephanie Willerth is an Associate Professor and Canada Research Chair at the University of Victoria. Her research focuses on using engineering-based approaches to stem cell biology. Her team develops bioactive scaffolds for directing stem cell differentiation, and investigates the expression of transcription factors that regulates this process. The goal of her group's research is to develop engineered tissues that can be transplanted in the human nervous system to treat diseases like Parkinson's or repair damaged spinal cord tissue.Featured Resources:STEMdiff™ Neural System for hPSC-Based Neurological ModelingScience in VancouverResources and LinksA Druggable Target for Alzheimer's Disease - Researchers have identified a cholesterol product regulating Tau proteostasis, which could serve as a drug target for Alzheimer’s disease.New Biomarker and Drug Target for ALS - Using an iPSC model of human motor neurons, researchers discovered that the STMN2 gene may be a potential biomarker and therapeutic target for ALS.Generation of Lung Organoids - Researchers have developed a protocol for differentiating hPSCs into human lung and bud tip progenitor organoids.Scientists Grow Human Blood Vessels in a Dish - Scientists have grown functional human vascular organoids that can be used to model and study vascular diseases.Organoid-Induced Differentiation of T Cells - Artificial thymic organoids were used to generate mature T cells from PSCs, providing a renewable source for treatment. Photo Reference: Courtesy of Dr. Stephanie Willerth#footable_5807  {    font-family: inherit;    font-size: 14px;    }#footable_parent_5807 thead{    display: none;}#footable_parent_5807 a.nt_edit_link{    display: none;}#footable_parent_5807 td{    border-color: #fff;}#footable_parent_5807 img{    margin-top: 0px;}.semantic_ui .ui.table{  border: 0px solid !important;  }.semantic_ui .ui.table td {    padding: 0em;}                                                                        #footable_5808  {    font-family: inherit;    font-size: 14px;    }thead{    display: none;}#footable_parent_5808 a.nt_edit_link{    display: none;}#footable_parent_5808 td{    border-color: #fff;}#footable_parent_5808 img{    margin-top: 0px;}.semantic_ui .ui.table{  border: 0px solid !important;  }.semantic_ui .ui.table td {    padding: 0em;}                                                                        #footable_5807  {    font-family: inherit;    font-size: 14px;    }#footable_parent_5807 thead{    display: none;}#footable_parent_5807 a.nt_edit_link{    display: none;}#footable_parent_5807 td{    border-color: #fff;}#footable_parent_5807 img{    margin-top: 0px;}.semantic_ui .ui.table{  border: 0px solid !important;  }.semantic_ui .ui.table td {    padding: 0em;}                                                                        #footable_5808  {    font-family: inherit;    font-size: 14px;    }thead{    display: none;}#footable_parent_5808 a.nt_edit_link{    display: none;}#footable_parent_5808 td{    border-color: #fff;}#footable_parent_5808 img{    margin-top: 0px;}.semantic_ui .ui.table{  border: 0px solid !important;  }.semantic_ui .ui.table td {    padding: 0em;}                                                                        #footable_7265  {    font-family: inherit;    font-size: 14px;    }#footable_parent_7265 thead{    display: none;}#footable_parent_7265 a.nt_edit_link{    display: none;}#footable_parent_7265 td{    border-color: #fff;}#footable_parent_7265 img{    margin-top: 0px;}.semantic_ui .ui.table{  border: 0px solid !important;  }.

Guest: Dr. Stephanie Willerth is an Associate Professor and Canada Research Chair at the University of Victoria. Her research focuses on using engineering-based approaches to stem cell biology. Her team develops bioactive scaffolds for directing stem cell differentiation, and investigates the expression of transcription factors that regulates this process. The goal of her group's research is to develop engineered tissues that can be transplanted in the human nervous system to treat diseases like Parkinson's or repair damaged spinal cord tissue. Featured Resources: STEMdiff™ Neural System for hPSC-Based Neurological Modeling Science in Vancouver Resources and Links A Druggable Target for Alzheimer's Disease - Researchers have identified a cholesterol product regulating Tau proteostasis, which could serve as a drug target for Alzheimer’s disease. New Biomarker and Drug Target for ALS - Using an iPSC model of human motor neurons, researchers discovered that the STMN2 gene may be a potential biomarker and therapeutic target for ALS. Generation of Lung Organoids - Researchers have developed a protocol for differentiating hPSCs into human lung and bud tip progenitor organoids. Scientists Grow Human Blood Vessels in a Dish - Scientists have grown functional human vascular organoids that can be used to model and study vascular diseases. Organoid-Induced Differentiation of T Cells - Artificial thymic organoids were used to generate mature T cells from PSCs, providing a renewable source for treatment.   Photo Reference: Courtesy of Dr. Stephanie Willerth #footable_5807 { font-family: inherit; font-size: 14px; } #footable_parent_5807 thead { display: none; } #footable_parent_5807 a.nt_edit_link { display: none; } #footable_parent_5807 td { border-color: #fff; } #footable_parent_5807 img { margin-top: 0px; } .semantic_ui .ui.table { border: 0px solid !important; } .semantic_ui .ui.table td { padding: 0em; } #footable_5808 { font-family: inherit; font-size: 14px; } thead { display: none; } #footable_parent_5808 a.nt_edit_link { display: none; } #footable_parent_5808 td { border-color: #fff; } #footable_parent_5808 img { margin-top: 0px; } .semantic_ui .ui.table { border: 0px solid !important; } .semantic_ui .ui.table td { padding: 0em; } #footable_5807 { font-family: inherit; font-size: 14px; } #footable_parent_5807 thead { display: none; } #footable_parent_5807 a.nt_edit_link { display: none; } #footable_parent_5807 td { border-color: #fff; } #footable_parent_5807 img { margin-top: 0px; } .semantic_ui .ui.table { border: 0px solid !important; } .semantic_ui .ui.table td { padding: 0em; } #footable_5808 { font-family: inherit; font-size: 14px; } thead { display: none; } #footable_parent_5808 a.nt_edit_link { display: none; } #footable_parent_5808 td { border-color: #fff; } #footable_parent_5808 img { margin-top: 0px; } .semantic_ui .ui.table { border: 0px solid !important; } .semantic_ui .ui.table td { padding: 0em; } #footable_7265 { font-family: inherit; font-size: 14px; } #footable_parent_7265 thead { display: none; } #footable_parent_7265 a.nt_edit_link { display: none; } #footable_parent_7265 td { border-color: #fff; } #footable_parent_7265 img { margin-top: 0px; } .semantic_ui .ui.table { border: 0px solid !important; } .

Ep. 135: “3D Bioprinting and Tissue Engineering” Featuring Dr. Stephanie Willerth